CoChat

Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

Open access
Moss, Arthur J., Windle, John R., Hall, W. Jackson, Zareba, Wojciech, Robinson, Jennifer L, McNitt, Scott, Severski, Patricia, Rosero, Spencer, Daubert, James P., Qi, Ming, Cieciorka, Michael, Manalan, Allan S. · 2005 · Annals of Noninvasive Electrocardiology
Cited by 145

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: We conducted a study of chronic therapy with flecainide versus placebo in a small group of LQT‐3 patients with the ΔKPQ deletion to evaluate the safety and efficacy of flecainide in this genetic disorder. In vitro studies have shown that flecainide provides correction of the impaired inactivation associated with the ΔKPQ deletion. Methods:A randomized, double‐blind, placebo‐controlled clinical trial was conducted with flecainide and placebo in six male LQT‐3 subjects with the ΔKPQ deletion. Results:The lowest possible dose of flecainide associated with at least a 40 ms reduction in the QTc interval was determined in an initial open‐label, dose‐ranging investigation using one‐fourth or half of the recommended maximal antiarrhythmic flecainide dose. QTc reduction was achieved with a flecainide dose of 1.5 mg/kg per day in 4 subjects and with 3.0 mg/kg per day in 2 subjects. Subjects were randomized to four 6‐month alternating periods of flecainide and placebo therapy based on the open‐label dose findings. Average QTc values during placebo and flecainide therapies were 534 ms and 503 ms, respectively, with an adjusted reduction in QTc of −27.1 ms (95% confidence interval: −36.8 ms to −17.4 ms; P < 0.001) at a mean flecainide blood level of 0.11 ±0.05 μg/ml. Minimal prolongation in QRS occurred (mean: +2.5 ms), and there were no major adverse cardiac effects. Conclusions:Chronic low‐dose flecainide significantly shortens the QTc interval in LQT‐3 subjects with the ΔKPQ mutation. No major adverse drug effects were observed with flecainide during this trial, but the sample size is not large enough to evaluate the safety of flecainide therapy in patients with this mutation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1542-474x.2005.00077.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death

    Mohler, P. J., Schott, J.-J., Gramolini, A. O., Dilly, K. W., Guatimosim, S., duBell, W. H., Song, L.-S., Haurogné, K., Kyndt, F., Ali, M. E., et al. (2003) · Nature · doi:10.1038/nature01335 · Cited by 957 · cited 1×

    “40; (4) women of child-bearing age not receiving appropriate contraceptive therapy; (5) weight <35 kg; (6) evidence of prior sensitivity to flecainide; (7) renal disease that might adversely effect drug excretion; (8) psychosocial problems that could compromise compliance with the protocol; (9) subjects who live at su…”
    Background

Show all 1 references

Cited by

See all 145

Metadata

Authors
Moss, A. J., Windle, J. R., Hall, W. J., Zareba, W., Robinson, J. L., McNitt, S., Severski, P., Rosero, S., Daubert, J. P., Qi, M., Cieciorka, M., & Manalan, A. S.
Venue
Annals of Noninvasive Electrocardiology
Publisher
Wiley
Published
2005-10
Volume
10
Issue
s4
Pages
59-66
ISSN
  • 1082-720X (ISSN-L)
  • 1542-474X
OpenAlex
W2143592728
Cited by
145
References
1
FWCI
4.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial. https://app.cochat.ai/papers/10.1111/j.1542-474x.2005.00077.x
The paper
Moss, A. J., Windle, J. R., Hall, W. J., Zareba, W., Robinson, J. L., McNitt, S., Severski, P., Rosero, S., Daubert, J. P., Qi, M., Cieciorka, M., & Manalan, A. S. (2005). Safety and Efficacy of Flecainide in Subjects with Long QT‐3 Syndrome (ΔKPQ Mutation): A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial. Annals of Noninvasive Electrocardiology. https://doi.org/10.1111/j.1542-474x.2005.00077.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.